ATP/ADP biosensor organoids for drug nephrotoxicity assessment
Frontiers in Cell and Developmental Biology · 02.03.2023 · 11
DOI: 10.3389/fcell.2023.1138504 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 02.03.2023. Verfasst von Koichiro Susa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Drug nephrotoxicity is a common healthcare problem in hospitalized patients and a major limitation during drug development. Multi-segmented kidney organoids derived from human pluripotent stem cells may complement traditional cell culture and animal experiments for nephrotoxicity assessment. Here we evaluate the capability of kidney organoids to investigate drug toxicity in vitro . Kidney organoids express renal drug transporters, OAT1, OAT3, and OCT2, while a human proximal tubular cell line shows the absence of OAT1 and OAT3. Tenofovir and aristolochic acid (AA) induce proximal tubular injury in organoids which is ameliorated by an OAT inhibitor, probenecid, without damage to podocytes. Similarly, cisplatin causes proximal tubular damage that can be relieved by an OCT inhibitor, cimetidine, collectively suggesting the presence of functional OATs and OCTs in organoid proximal tubules. Puromycin aminonucleoside (PAN) induced segment-specific injury in glomerular podocytes in kidney organoids in the absence of tubular injury. Reporter organoids were generated with an ATP/ADP biosensor, which may be applicable to high-throughput screening in the future. In conclusion, the kidney organoid is a useful tool for toxicity assessment in the multicellular context and may contribute to nephrotoxicity assessment during drug development.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States.
- Harvard Medical School, Boston, MA, United States.
- Department of Nephrology, Tokyo Medical and Dental University, Tokyo, Japan.
- Massachusetts General Hospital, Boston, MA, United States.
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, United States.
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States.
Förderung
- NIDDK NIH HHS
- NCATS NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences
Zitieren
APA
Susa, K., Kobayashi, K., Galichon, P., Matsumoto, T., Tamura, A., Hiratsuka, K., Gupta, N. R., Yazdi, I. K., Bonventre, J. V., & Morizane, R. (2023). ATP/ADP biosensor organoids for drug nephrotoxicity assessment. Frontiers in Cell and Developmental Biology, 11. https://doi.org/10.3389/fcell.2023.1138504
Vancouver
Susa K, Kobayashi K, Galichon P, Matsumoto T, Tamura A, Hiratsuka K, et al. ATP/ADP biosensor organoids for drug nephrotoxicity assessment. Frontiers in Cell and Developmental Biology. 2023;11. doi:10.3389/fcell.2023.1138504
BibTeX
@article{Susa2023,
author = {Susa, Koichiro and Kobayashi, Kenichi and Galichon, Pierre and Matsumoto, Takuya and Tamura, Akitoshi and Hiratsuka, Ken and Gupta, Navin R and Yazdi, Iman K and Bonventre, Joseph V and Morizane, Ryuji},
title = {ATP/ADP biosensor organoids for drug nephrotoxicity assessment},
journal = {Frontiers in Cell and Developmental Biology},
year = {2023},
volume = {11},
doi = {10.3389/fcell.2023.1138504}
}
EUVIMED